Análisis Argos
AMRX
AMRXEn su precio
Amneal Pharmaceuticals, Inc. · Healthcare
US$ 17.15
precio al 2026-07-04
Valor justo Argos*
US$ 12–15
vs. su valor justo
28% por encima
Score Argos
57/100
En su precio
LA RESPUESTA
El precio asume un crecimiento (15.8%) en línea con lo que la empresa demuestra (12%). Ni ganga ni exceso — el mercado le puso un precio razonable.
Recompensas
Retorno sobre el capital alto (17%).
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
VALOR3/6FUTURO3/6PASADO5/6SALUD1/6DIVIDENDO1/6
El Iris de calidad
VALOR3/6FUTURO3/6PASADO5/6SALUD1/6DIVIDENDO1/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance frágil
DividendoEl dividendo aún duerme
Score Argos57de 100En su precio
Ingresos8%
US$ 3 B
Margen operativo57%
14%
Flujo de caja libre23%
US$ 0.3 B
Deuda neta
US$ 2.4 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 5.5B
P/E76x
EV/EBITDA12.2x
FCF yield4.9%
ROIC16.5%
Margen operativo14%
Crecim. ingresos+8.0%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 2 jul
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
globenewswire.com · 29 jun
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations
MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens.
zacks.com · 24 jun
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
forbes.com · 17 jun
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
zacks.com · 11 jun
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
gurufocus.com · 10 jun
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued
On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current price to $15.32. This price is within a 52-week range that has
gurufocus.com · 10 jun
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVI
prnewswire.com · 10 jun
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hope announced the launch of its national "Hope Alliance" campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across the United States.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.